162 related articles for article (PubMed ID: 29037255)
41. In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival.
Ladoire S; Mignot G; Dabakuyo S; Arnould L; Apetoh L; Rébé C; Coudert B; Martin F; Bizollon MH; Vanoli A; Coutant C; Fumoleau P; Bonnetain F; Ghiringhelli F
J Pathol; 2011 Jul; 224(3):389-400. PubMed ID: 21437909
[TBL] [Abstract][Full Text] [Related]
42. Association of Notch pathway down-regulation with Triple Negative/Basal-like breast carcinomas and high tumor-infiltrating FOXP3+ Tregs.
Ortiz-Martínez F; Gutiérrez-Aviñó FJ; Sanmartín E; Pomares-Navarro E; Villalba-Riquelme C; García-Martínez A; Lerma E; Peiró G
Exp Mol Pathol; 2016 Jun; 100(3):460-8. PubMed ID: 27118257
[TBL] [Abstract][Full Text] [Related]
43. Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy.
Liu S; Duan X; Xu L; Xin L; Cheng Y; Liu Q; Ye J; Zhang S; Zhang H; Zhu S; Li T; Liu Y
Breast Cancer Res Treat; 2015 Nov; 154(2):239-49. PubMed ID: 26498019
[TBL] [Abstract][Full Text] [Related]
44. Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab.
Lee HJ; Kim JY; Park IA; Song IH; Yu JH; Ahn JH; Gong G
Am J Clin Pathol; 2015 Aug; 144(2):278-88. PubMed ID: 26185313
[TBL] [Abstract][Full Text] [Related]
45. In situ localization of tumor cells associated with the epithelial-mesenchymal transition marker Snail and the prognostic impact of lymphocytes in the tumor microenvironment in invasive ductal breast cancer.
Alkatout I; Hübner F; Wenners A; Hedderich J; Wiedermann M; Sánchez C; Röcken C; Mathiak M; Maass N; Klapper W
Exp Mol Pathol; 2017 Apr; 102(2):268-275. PubMed ID: 28232080
[TBL] [Abstract][Full Text] [Related]
46. Prognostic value of tumor PD-L1 expression combined with CD8
Wang Q; Lou W; Di W; Wu X
Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
[TBL] [Abstract][Full Text] [Related]
47. Correlation of tumor-infiltrative lymphocyte subtypes alteration with neoangiogenesis before and after neoadjuvant chemotherapy treatment in breast cancer patients.
Chan MS; Chen SF; Felizola SJ; Wang L; Nemoto N; Tamaki K; Ishida T; Chow LW; Ohuchi N; Sasano H
Int J Biol Markers; 2014 Sep; 29(3):e193-203. PubMed ID: 24803281
[TBL] [Abstract][Full Text] [Related]
48. Association of Increased Treg Cell Levels With Elevated Indoleamine 2,3-Dioxygenase Activity and an Imbalanced Kynurenine Pathway in Interferon-Positive Primary Sjögren's Syndrome.
Maria NI; van Helden-Meeuwsen CG; Brkic Z; Paulissen SM; Steenwijk EC; Dalm VA; van Daele PL; Martin van Hagen P; Kroese FG; van Roon JA; Harkin A; Dik WA; Drexhage HA; Lubberts E; Versnel MA
Arthritis Rheumatol; 2016 Jul; 68(7):1688-99. PubMed ID: 26866723
[TBL] [Abstract][Full Text] [Related]
49. T Lymphocyte Infiltration in Association with IDO1 Expression in Resected Lung Adenocarcinoma and Normal Adjacent Lung Tissues.
Zhao X; Li Y; Yang X; Zhang X; Xie J; Li S; Liu H; Guo J; He L; Chen W; Liu D
Biomed Res Int; 2022; 2022():2381018. PubMed ID: 35187162
[TBL] [Abstract][Full Text] [Related]
50. Suppression of indoleamine-2,3-dioxygenase 1 expression by promoter hypermethylation in ER-positive breast cancer.
Dewi DL; Mohapatra SR; Blanco Cabañes S; Adam I; Somarribas Patterson LF; Berdel B; Kahloon M; Thürmann L; Loth S; Heilmann K; Weichenhan D; Mücke O; Heiland I; Wimberger P; Kuhlmann JD; Kellner KH; Schott S; Plass C; Platten M; Gerhäuser C; Trump S; Opitz CA
Oncoimmunology; 2017; 6(2):e1274477. PubMed ID: 28344890
[TBL] [Abstract][Full Text] [Related]
51. Tumor-Infiltrating CD8+ T Cells Driven by the Immune Checkpoint-Associated Gene IDO1 Are Associated With Cervical Cancer Prognosis.
Zhang S; Wan J; Chen M; Cai D; Xu J; Chen Q
Front Oncol; 2021; 11():720447. PubMed ID: 34778035
[TBL] [Abstract][Full Text] [Related]
52. Development of a DNA aptamer targeting IDO1 with anti-tumor effects.
Zhu Z; Yang Z; Zhu C; Hu Z; Jiang Z; Gong J; Yuan Y; Chen X; Jin Y; Yin Y
iScience; 2023 Aug; 26(8):107367. PubMed ID: 37520707
[TBL] [Abstract][Full Text] [Related]
53. Pathomic model based on histopathological features and machine learning to predict IDO1 status and its association with breast cancer prognosis.
Zhuo X; Deng H; Qiu M; Qiu X
Breast Cancer Res Treat; 2024 May; ():. PubMed ID: 38780888
[TBL] [Abstract][Full Text] [Related]
54. CXCR4 antagonism in combination with IDO1 inhibition weakens immune suppression and inhibits tumor growth in mouse breast cancer bone metastases.
Zhang J; Pang Y; Xie T; Zhu L
Onco Targets Ther; 2019; 12():4985-4992. PubMed ID: 31388305
[TBL] [Abstract][Full Text] [Related]
55. Comprehensive analysis of the prognostic value and immune function of the
Zhou Q; Cao FH; Liu H; Zuo MZ
Am J Transl Res; 2021; 13(4):2041-2059. PubMed ID: 34017374
[TBL] [Abstract][Full Text] [Related]
56. IDO1 facilitates esophageal carcinoma progression by driving the direct binding of NF-κB and CXCL10.
Yao W; Cui X; Peng H; Zhang Y; Jia X; Wu S; Zhao J
Cell Death Discov; 2023 Oct; 9(1):403. PubMed ID: 37903782
[TBL] [Abstract][Full Text] [Related]
57. Answer to the Teresa Pusiol comments to the paper "The association of tumor lymphocyte infiltration with clinico-pathological factor and survival in breast cancer" by Huszno et al .
Huszno J; Zembala-Nożyńska E; Lange D; Kołosza Z; Nowara E
Pol J Pathol; 2017; 68(3):269. PubMed ID: 29363921
[No Abstract] [Full Text] [Related]
58. A novel immunohistochemical score to predict early mortality in acute myeloid leukemia patients based on indoleamine 2,3 dioxygenase expression.
Mangaonkar A; Mondal AK; Fulzule S; Pundkar C; Park EJ; Jillella A; Kota V; Xu H; Savage NM; Shi H; Munn D; Kolhe R
Sci Rep; 2017 Oct; 7(1):12892. PubMed ID: 29038460
[TBL] [Abstract][Full Text] [Related]
59. Blocking IDO1 Helps Shrink Bladder, Cervical Tumors.
Cancer Discov; 2018 Jan; 8(1):OF3. PubMed ID: 29167110
[TBL] [Abstract][Full Text] [Related]
60. Investigation of the Tissue Distribution and Physiological Roles of Indoleamine 2,3-Dioxygenase-2.
Jusof FF; Bakmiwewa SM; Weiser S; Too LK; Metz R; Prendergast GC; Fraser ST; Hunt NH; Ball HJ
Int J Tryptophan Res; 2017; 10():1178646917735098. PubMed ID: 29051706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
